Sign In
Get Clay Free →

Suggestions

    Osman Ozes

    Founder and Chief Scientific Officer at Altay Therpaeutics Inc.

    Osman Ozes is a highly accomplished scientist with a rich background in academic and industry research spanning over 30 years in academia and 10 years in industry. With a focus on fibrosis, cancer immunology, inflammatory diseases, and biomarkers, Osman has made significant contributions to the field of medicine. As the former Director of Research at Intermune Inc., he led a large team, excelling in communication, leadership, and organization. Notable achievements include characterizing the mechanism of action of Pirfenidone (Esbriet) crucial for FDA approval for lung fibrosis treatment, leading to Roche's acquisition of Intermune for $8.3 billion. As a Genetics professor at Akdeniz University, Osman mentored numerous PhD students in diverse fields. Additionally, he founded Link Biopharma, identifying anti-fibrotic drug candidates and filing a US patent application in 2017. Osman possesses expertise in pre-clinical and clinical-stage drug development, biomarker identification, pathway analysis, and signal transduction of various molecules like cytokines, oncogenes, and growth factors.

    Osman Ozes
    Add to my network

    Location

    San Bruno, California, United States